NHS directed to boost hep C testing, but guidance falls short of concerns
This article was originally published in Clinica
Executive Summary
The UK's chief medical and chief nursing officers have written to all NHS primary care trusts (PCTs), urging them to improve the rates of detection and diagnosis of hepatitis C, with a focus on pre-emptive and confirmatory testing. The move will go some way to assuaging the Hepatitis C Trust (HCT), the UK's leading lobby and patient support group, but falls short of fully meeting its concerns, as submitted to the health select committee (HSC) for its recently-launched inquiry into patient safety*.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.